USANA Health Sciences (USNA) Stock Price, News & Analysis

Company Overview

USANA Health Sciences, Inc. is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America. Key regions of operation include the United States, Canada, China, Taiwan, Australia, the United Kingdom and Mexico. The company leverages a multilevel marketing structure, enabling independent distributors to earn commissions on personal sales and the sales of their recruited team members.

USANA’s manufacturing facilities are located in Salt Lake City, Utah, and in Tlalnepantla, Mexico, providing global production capacity to support demand. The company has emphasized scientific validation of its products and maintains partnerships with third‐party research institutions. Through its focus on health sciences and peer‐reviewed studies, USANA positions itself as a science‐driven provider of wellness solutions.

Key Stats

• Today's Range: $20.54 to $21.39
• 50-Day Range: $20.22 to $32.20
• 52-Week Range: $19.88 to $41.83
• Volume: 89,869 shs
• Average Volume: 173,917 shs
• Market Capitalization: $384.04 million
• P/E Ratio: 11.70
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Reduce

USANA Health Sciences Stock Analysis - MarketRank™

USANA Health Sciences scored higher than 90% of companies evaluated by MarketBeat, and ranked 89th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

USANA Health Sciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

USANA Health Sciences has a consensus price target of $36.00, representing about 70.4% upside from its current price of $21.13.

Amount of Analyst Coverage

USANA Health Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 17.96%

Earnings Growth

Earnings for USANA Health Sciences are expected to grow by 17.96% in the coming year, from $2.45 to $2.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of USANA Health Sciences is 11.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.25.

Price to Earnings Ratio vs. Sector

The P/E ratio of USANA Health Sciences is 11.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.24.

Price to Earnings Growth Ratio

USANA Health Sciences has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

USANA Health Sciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.35% of the float of USANA Health Sciences has been sold short.

Short Interest Ratio / Days to Cover

USANA Health Sciences has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in USANA Health Sciences has recently increased by 3.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

USANA Health Sciences does not currently pay a dividend.

Dividend Growth

USANA Health Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -2.01

Percentage of Shares Shorted

6.35% of the float of USANA Health Sciences has been sold short.

Short Interest Ratio / Days to Cover

USANA Health Sciences has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in USANA Health Sciences has recently increased by 3.06%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.42

News Sentiment

USANA Health Sciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for USANA Health Sciences this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,152.00 in company stock.

Percentage Held by Insiders

Only 0.63% of the stock of USANA Health Sciences is held by insiders.

Percentage Held by Institutions

54.25% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

USNA Stock Analysis - Frequently Asked Questions

How have USNA shares performed this year?

USANA Health Sciences' stock was trading at $35.89 on January 1st, 2025. Since then, USNA stock has decreased by 41.1% and is now trading at $21.13.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Thursday, October, 9th. The company reported $0.56 earnings per share (EPS) for the quarter. The business earned $200.22 million during the quarter. USANA Health Sciences had a net margin of 3.79% and a trailing twelve-month return on equity of 9.48%.

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' top institutional investors include Assenagon Asset Management S.A. (0.56%), Exchange Traded Concepts LLC (0.26%), Inspire Investing LLC (0.09%) and CWM LLC (0.03%). Insiders that own company stock include Myron W Wentz, Jim Brown, Kevin Guest, David Mulham Mulham, John Turman Fleming, Peggie Pelosi, Frederic J Winssinger, Xia Ding, Walter Noot, Robert A Sinnott, Paul A Jones, Joshua Foukas, Gilbert A Fuller, G Doug Iiekking, Daniel A Macuga and Brent Neidig.
View institutional ownership trends.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that USANA Health Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 10/09/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 10/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Personal Products
• Current Symbol: NYSE:USNA
• CIK: 896264
• Web: www.usana.com
• Phone: (801) 954-7100
• Fax: 801-954-7300
• Employees: 1,700
• Year Founded: 1992

Price Target and Rating

• Average Price Target for USANA Health Sciences: $36.00
• High Price Target: $36.00
• Low Price Target: $36.00
• Potential Upside/Downside: +73.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.80
• Trailing P/E Ratio: 11.50
• Forward P/E Ratio: 8.45
• P/E Growth: 1.02
• Net Income: $42.03 million
• Net Margins: 3.79%
• Pretax Margin: 7.18%
• Return on Equity: 9.48%
• Return on Assets: 6.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 1.47

Sales & Book Value

• Annual Sales: $854.50 million
• Price / Sales: 0.44
• Cash Flow: $3.74 per share
• Price / Cash Flow: 5.53
• Book Value: $27.92 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 18,270,000
• Free Float: 18,157,000
• Market Cap: $378.28 million
• Optionable: Optionable
• Beta: 0.61